This scoping review examines the use of CRISPR/Cas9 gene editing in glioblastoma (GBM), a highly aggressive brain tumor. The review categorizes gene targets into distinct groups, including cell cycle regulation, microenvironmental dynamics, interphase processes, and therapy resistance reduction. CRISPR/Cas9 technology is highlighted for its potential in unraveling the complex dynamics of the GBM microenvironment and offering promising avenues for targeted therapies. The review also addresses studies that challenge conventional perspectives on specific genes, emphasizing the therapeutic implications of manipulating key molecular players in cell cycle dynamics. The findings underscore the potential of CRISPR/Cas9 in reducing GBM growth and improving patient outcomes. Additionally, the review explores the application of CRISPR/Cas9 in addressing therapy resistance, particularly in chemotherapy and radiotherapy. Despite the promising results, the review highlights the need for further research to address safety concerns, such as off-target effects and immunogenic toxicity, to ensure the successful clinical application of CRISPR/Cas9 technology in GBM treatment.This scoping review examines the use of CRISPR/Cas9 gene editing in glioblastoma (GBM), a highly aggressive brain tumor. The review categorizes gene targets into distinct groups, including cell cycle regulation, microenvironmental dynamics, interphase processes, and therapy resistance reduction. CRISPR/Cas9 technology is highlighted for its potential in unraveling the complex dynamics of the GBM microenvironment and offering promising avenues for targeted therapies. The review also addresses studies that challenge conventional perspectives on specific genes, emphasizing the therapeutic implications of manipulating key molecular players in cell cycle dynamics. The findings underscore the potential of CRISPR/Cas9 in reducing GBM growth and improving patient outcomes. Additionally, the review explores the application of CRISPR/Cas9 in addressing therapy resistance, particularly in chemotherapy and radiotherapy. Despite the promising results, the review highlights the need for further research to address safety concerns, such as off-target effects and immunogenic toxicity, to ensure the successful clinical application of CRISPR/Cas9 technology in GBM treatment.